SHIP-deficiency to increase megakaryocyte progenitor production

Details SHIP-deficiency to increase megakaryocyte progenitor production SHIP-deficiency to increase megakaryocyte progenitor production

2004-11-22

2010-10-05

Chong, Kimberly (Department: 1635)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C536S024500, C536S024310, C536S024100

Reexamination Certificate

active

07807646

ABSTRACT:
A method of increasing megakaryocytes and platelet numbers in a patient comprising the step of inhibiting SHIP expression, including SHIP's enzymatic activity and signaling functions, whereby normal blood clotting is induced.

REFERENCES:
patent: 4603112 (1986-07-01), Paoletti et al.
patent: 4769330 (1988-09-01), Paoletti et al.
patent: 4777127 (1988-10-01), Suni et al.
patent: 5017487 (1991-05-01), Stunnenberg et al.
patent: 5166057 (1992-11-01), Palese et al.
patent: 5804412 (1998-09-01), Gill et al.
patent: 6025198 (2000-02-01), Bennett et al.
patent: 6090621 (2000-07-01), Kavanaugh et al.
patent: 6117850 (2000-09-01), Patchen et al.
patent: 6506559 (2003-01-01), Fire et al.
patent: 6703215 (2004-03-01), Erneux
patent: 2002/0137711 (2002-09-01), Kerr
patent: 2002/0165192 (2002-11-01), Kerr et al.
patent: 2003/0114401 (2003-06-01), Bennett et al.
patent: 2003/0143732 (2003-07-01), Fosnaugh et al.
patent: 2003/0166282 (2003-09-01), Brown et al.
patent: 2004/0072298 (2004-04-01), Sauvageau et al.
patent: 2004/0235765 (2004-11-01), Kerr et al.
patent: 2004/0259247 (2004-12-01), Tuschl et al.
patent: 2005/0054103 (2005-03-01), Peled et al.
patent: 2006/0223749 (2006-10-01), Desponts et al.
patent: 2007/0224124 (2007-09-01), Kerr et al.
patent: 2008/0076731 (2008-03-01), Kerr
patent: 0 345 242 (1989-12-01), None
patent: 0 440 219 (1991-08-01), None
patent: 2 200 651 (1988-08-01), None
patent: WO 89/01973 (1989-03-01), None
patent: WO 91/02805 (1991-03-01), None
patent: WO 92/06693 (1992-04-01), None
patent: WO 97/10252 (1997-03-01), None
patent: WO 97/12039 (1997-04-01), None
patent: WO 99/32619 (1999-07-01), None
patent: WO 02/24233 (2002-03-01), None
patent: WO 02/44321 (2002-06-01), None
patent: WO 02/078614 (2002-10-01), None
patent: WO 2009/042910 (2009-04-01), None
Pasquet et al. Phosphatidylinositol 3,4,5-triphosphate regulates CA2 entry via Btk in platelets and megakaryocytes without increasing phospholipase C activity. EMBO Journal. 2000. vol. 19, No. 12 : 2793-2802.
Wang et al. Influence of SHIP on the NK repertoire and allogeneic bone marrow transplantation. Science 2002, vol. 295: 2094-2097.
Ahmed et al. Cytokine induced expansion of human CD34+ stem/progenitor and CD34+/CD41+ early megakaryocytic marrow cells cultured on normal osteoblasts. Stem Cells 1999, vol. 17: 92-99.
Helgason et al. Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, and shortened life span. Genes and Development 1998, vol. 12; pp. 1610-1620.
U.S. Appl. No. 10/605,452, filed Sep. 30, 2003, Kerr et al.
U.S. Appl. No. 10/709,801, filed May 28, 2004, Desponts et al.
Agrawal, S. “Antisense oligonucleotides: towards clinical trials”TIBTECH, 1996, 14:376-387.
Agrawal, S. and Kandimalla, E. “Antisense therapeutics: is it as simple as complementary base recognition?”Molecular Med. Today, 2000, 6:72-81.
Akagi, K. et al. “Cre-mediated somatic site-specific recombination in mice”Nucleic Acids Res, 1997; 25(9):1766-1773.
Bender, M.A. et al. “Description and targeted deletion of 5′ hypersensitive site 5 and 6 of the mouse β-globin locus control region”Blood, 1998, 92:4394-4403.
Braasch, D.A. and Corey, D.R. “Novel antisense and peptide nucleic acid strategies for controlling gene expression”Biochemistry, 2002, 41(14):4503-4510.
Branch, A. “A good antisense molecule is hard to find”Trends in Biochem., 1998, 23:45-50.
Cantley, L.C. et al. “Oncogenes and signal transduction”Cell, 1991, 64:281-302.
Chirila, T. et al. “The use of synthetic polymers for delivery of therapeutic antisense oligodeoxynucleotides”Biomaterials, 2002, 23:321-342.
Crooke, S.T. “Basic principles of antisense therapeutics” in Antisense Res. and Application, chapter 1, pp. 1-50, S. Crooke, Ed., Springer-Verlag, 1999.
Desponts, C. et al. “MHC class I inhibitory receptors on natural killer cells recruit SHIP in an attempt to control cell survival”FASEB Journal, Mar. 20, 2002, 16(4):A706, abstract.
Evans, D.J. et al. “An engineered poliovirus chimaera elicits broadly reactive HIV-1 neutralizing antibodies”Nature, 1989, 339:385-388.
Fisher-Hoch, S.P. et al. “Protection of rhesus monkeys from fatal Lassa fever by vaccination with recombinant vaccinia virus containing the Lassa virus glycoprotein gene”PNAS, 1989, 86:317-321.
Gewirtz. A.M. et al. “Facilitating oligonucleotide delivery: Helping antisense deliver on its promise”Proc. Natl. Acad. Sci. USA, 1996, 93:3161-3163.
Ghansah, T. et al. “A role for the SH2-containing inositol phosphatase in the biology of natural killer cells and stem cells” Activating and Inhibitory Immunoglobulin-like Receptors, 2001, pp. 129-140.
Ghansah, T. et al. “Target disruption of Src homology 2-containing 5′ inositol phosphatase (SHIP) alters PI3K/AKT and MAPK signal transduction pathways in murine natural killer cells”FASEB Journal, Mar. 20, 2002, 16(4):A706, abstract.
Ghansah, T. et al. “The Src homology 2 containing inositol phosphatase is vital for the function and homeostatis of Natural Killer cells”FASEB Journal, Mar. 7, 2001, 15(4):A655, abstract.
Guzman, R.J. et al. “Molecular and cellular cardiology/receptors: efficient and selective adenovirus-mediated gene transfer into vascular neointima”Circulation, 1993, 88(6):2838-2848.
Hawkins, P.T. et al. “Platelet-derived growth factor stimulates synthesis of Ptdlns(3,4,5)P3by activating a Ptdlns(4,5)P23-OH kinase”Nature, 1992, 358:157-910.
Held, W. et al. “Transgenic expression of the Ly49A natural killer cell receptor confers class I major histocompatibility complex (MHC)-specific inhibition and prevents bone marrow allograft rejection”J. Exp. Med., 1996, 184(5):2037-2041.
Helgason; C.D. et al. “Homeostasis and regeneration of the hematopoietic stem cell pool are altered in SHIP-deficient mice”Blood, 2003, 102(10):3541-3547.
Helgason, C.D. et al. “Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, and a shortened life span”Genes&Dev., 1998, 12(11):1610-1620.
Huber, M. et al. “The src homology 2-containing inositol phosphatase (SHIP) is the gatekeeper of mast cell degranulation”Proc. Natl. Acad. Sci. USA, 1998, 95(19):11330-11335.
Jefferson, A.B. et al. “Properties of type II inositol polyphosphate 5-phosphatase”J. Biol. Chem., 1995, 270(16):9370-9377.
Jen, K-Y and Gewirtz, A.M. “Suppression of gene expression by targeted disruption of messenger RNA: Available options and current strategies”Stem Cells, 2000, 18:307-319.
Jolly, D. et al. “Viral vector systems for gene therapy”Cancer Gene Therapy, 1998, 1(1):51-64.
Kass-Eisler, A. et al. “Quantitative determination of adenovirus-mediated gene delivery to rat cardiac myocytes in vitro and in vivo”PNAS, 1993, 90:11498-11502.
Kerr, William G. et al., Critical Role for SHIP in engraftment of histo-incompatible stem cells, Oncology Research, 2001, 12:285.
Klippel, A. et al. “Membrane localization of phosphatidylinositol 3-kinase is sufficient to activate multiple signal-transducing kinase pathways”Mol Cell. Biol., 1996, 16(8):4117-4127.
Koh, C. et al. “Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo”Blood, 2001, 97(10):3132-3137.
Kolls, J. et al. “Prolonged and effective blockade of tumor necrosis factor activity through adenovirus-mediated gene transfer”PNAS, 1994, 91:215-219.
Lanier, L.L. “NK cell receptors”Annual Rev of Immunology, 1998, 16:359-393.
Liu, L. et al. “The Src homology 2 (SH2) domain of SH2-containing inositol phosphatase (SHIP) is essential for tyrosine phosphorylation of SHIP, its association with Shc, and its induction of apoptosis”J. Biol. Chem., 1997, 272:8983-8988.
Liu, Q. et al. “SHIP is a negative regulator of growth factor receptor-media

Affiliated with

Also associated with

Rating

SHIP-deficiency to increase megakaryocyte progenitor production does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with SHIP-deficiency to increase megakaryocyte progenitor production, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and SHIP-deficiency to increase megakaryocyte progenitor production will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4203384